Clinical Trial Update: Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia [Phase 3]

View source ↗

Summary

Phase III trial evaluating DA-3031, a pegylated G-CSF, for chemotherapy-induced neutropenia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia

Drugs mentioned

• DA-3031 (pegylated granulocyte colony-stimulating factor (PEG-G-CSF))

Snippet

Sponsor: Dong-A ST Co., Ltd. | Conditions: Chemotherapy Induced Neutropenia | Phase 3 | Status: COMPLETED